There is no doubt that patients who continue maintenance Revlimid (lenalidomide) following autologous transplant do better than those who do not. Dr. Phil McCarthy showed unequivocally in CALGB 100104 (Revlimid vs placebo) that progression free survival (PFS) and overall survival (OS) are longer for patients taking maintenance Revlimid. Likewise, maintenance therapy extends PFS for patients […]
The International Myeloma Foundation Social Media team has been active even though this year’s American Society of Hematology meeting is taking place virtually. Not only attending session virtually and engaging with researchers, clinicians, pharmaceutical representatives, and others; but also, coming together for virtual debriefs and virtual recharge. I miss seeing these myeloma friends in person, […]
Minimal Residual Disease (-) (meaning no detectable disease) has become the agreed goal of most myeloma clinical trials. MRD (-) status is a predictor of good outcome. As we patients progress with treatment we want to know if we have reached MRD (-) or not, however it is defined, and by whichever method it is measured. […]
The life expectancy of standard-risk myeloma patients has increased significantly in the last decade, thanks to novel therapies. Some trials that are in progress, such as the MAIA trial comparing Revilmid and dexamethasone (Rd) versus Daratumumab, Revilmid and dexamethasone (DRd) have not yet met their progression-free survival (PFS) end state and are at more than […]
